Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Chimeric Antigen Receptor (CAR) Therapy InfusionRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Active Trials
1(50%)

Phase Distribution

Phase 1
1
50%
Phase 2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

not_yet_recruiting150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
not_yet_recruitingphase_1

GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors

NCT07897968
recruitingphase_2

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

NCT05934448

Clinical Trials (2)

Showing 2 of 2 trials
NCT07897968Phase 1

GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors

Not Yet Recruiting
NCT05934448Phase 2

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
Varies by study
Total Trials
2